Home » Stocks » EARS

Auris Medical Holding Ltd. (EARS)

Stock Price: $3.39 USD -0.15 (-4.24%)
Updated Jun 15, 2021 4:00 PM EDT - Market closed
Pre-market: $3.40 +0.01 (0.30%) Jun 16, 8:20 AM
Market Cap 45.56M
Revenue (ttm) 174,475
Net Income (ttm) -8.20M
Shares Out 12.87M
EPS (ttm) -1.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 15
Last Price $3.39
Previous Close $3.54
Change ($) -0.15
Change (%) -4.24%
Day's Open 3.56
Day's Range 3.35 - 3.58
Day's Volume 260,635
52-Week Range 0.73 - 6.25

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Auris Medical Holding Ltd (NASDAQ:EARS) shares are trading higher by 12.7% at $4.16 Thursday morning after the company announced the acquisition of RNA therapeutics company Trasir Therapeutics and plans...

1 week ago - Benzinga

Auris Medical Holding Ltd (NASDAQ: EARS) has acquired privately-held Trasir Therapeutics Inc, focused on extrahepatic oligonucleotide delivery. The purchase price comprises 0.77 million common shares, t...

1 week ago - Benzinga

Hamilton, Bermuda, June 3, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhin...

1 week ago - GlobeNewsWire

Hamilton, Bermuda, June 1, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhin...

2 weeks ago - GlobeNewsWire

Hamilton, Bermuda, May 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhin...

2 weeks ago - GlobeNewsWire

Hamilton, Bermuda, May 25, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhin...

3 weeks ago - GlobeNewsWire

Hamilton, Bermuda, May 14, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhin...

1 month ago - GlobeNewsWire

Since late January, each time shares of Auris Medical Holding Ltd. (NASDAQ:EARS) fell to $2.80 a rally followed.

1 month ago - Benzinga

Meme penny stocks are a budding sector; have you heard of these 4? The post 4 Meme Penny Stocks To Watch As DogeCoin Rises appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStock...

Other stocks mentioned: BTU, CKPT, EBON
1 month ago - PennyStocks

Auris Medical Holding Ltd (NASDAQ: EARS) has announced additional information regarding the results from the clinical trial of its nasal spray, Bentrio, meant for treating people suffering from allergic...

1 month ago - Benzinga

Hamilton, Bermuda, May 7, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhino...

1 month ago - GlobeNewsWire

Hamilton, Bermuda, April 13, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rh...

2 months ago - GlobeNewsWire

Auris Medical Holding Ltd. (NASDAQ: EARS), CytoDyn Inc. (OTC: CYDY) and Prometheus Biosciences, Inc. (NASDAQ: RXDX) are among the biggest movers in the biopharma space Thursday.

Other stocks mentioned: CYDY, RXDX
2 months ago - Benzinga

Hamilton, Bermuda, April 8, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhi...

2 months ago - GlobeNewsWire

Hamilton, Bermuda, March 31, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rh...

2 months ago - GlobeNewsWire

Auris Medical (EARS) stock is heading higher on Tuesday with heavy trading of the shares despite a lack of news concerning the company. The post EARS Stock: 7 Things for Auris Medical Investors to Know ...

3 months ago - InvestorPlace

Auris Medical Holding Ltd. (NASDAQ: EARS) shares traded on increased volume during Friday's trading session.

3 months ago - Benzinga

Hamilton, Bermuda, January 29, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, ...

4 months ago - GlobeNewsWire

Hamilton, Bermuda, December 7, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, ...

6 months ago - GlobeNewsWire

Hamilton, Bermuda, December 2, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS) (“Auris” or the “Company”), a clinical-stage company dedicated to developing therapeutics that address important unmet med...

6 months ago - GlobeNewsWire

Auris Medical soared as high as 480% on Tuesday after it announced lab-test results that show its nasal spray could protect against the coronavirus. Shares of the Bermuda-based clinical stage company ar...

6 months ago - Business Insider

EARS stock typically flies under the radar, but today it is getting a boost thanks to trial data from a Covid-19 treatment. The post EARS Stock: Why Auris Medical Shares Are Soaring 450% appeared first ...

6 months ago - InvestorPlace

Auris Medical (NASDAQ: EARS) shares are ripping higher on Tuesday after the company reported positive efficacy data for its AM-301 in protecting against Sars COVID-19 infections. Auris Medical Holding L...

6 months ago - Benzinga

Hamilton, Bermuda, December 1, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, ...

6 months ago - GlobeNewsWire

Hamilton, Bermuda, November 20, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology,...

6 months ago - GlobeNewsWire

Auris Medical (EARS) news for Tuesday includes the start of enrollment for the second part of a Phase 2 study to treat acute vertigo. The post Auris Medical News: Why EARS Stock Is Soaring 24% Today app...

8 months ago - InvestorPlace

Hamilton, Bermuda, October 13, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology a...

8 months ago - GlobeNewsWire

Auris Medical Holding Ltd. (EARS) CEO Thomas Meyer on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Hamilton, Bermuda, September 17, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...

8 months ago - GlobeNewsWire

Hamilton, Bermuda, September 11, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...

9 months ago - GlobeNewsWire

Hamilton, Bermuda, September 8, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology ...

9 months ago - GlobeNewsWire

Hamilton, Bermuda, September 3, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology ...

9 months ago - GlobeNewsWire

Hamilton, Bermuda, August 20, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology an...

9 months ago - GlobeNewsWire

Hamilton, Bermuda, July 29, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and ...

10 months ago - GlobeNewsWire

Hamilton, Bermuda, May 26, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and c...

1 year ago - GlobeNewsWire

       Hamilton, Bermuda, April 16, 2020 – Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotolog...

1 year ago - GlobeNewsWire

Hamilton, Bermuda, April 3, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and ...

1 year ago - GlobeNewsWire

Hamilton, Bermuda, March 5, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and ...

1 year ago - GlobeNewsWire

Hamilton, Bermuda, February 25, 2020 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology an...

1 year ago - GlobeNewsWire

Hamilton, Bermuda, January 10, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology a...

1 year ago - GlobeNewsWire

Hamilton, Bermuda, Dec. 30, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs...

1 year ago - GlobeNewsWire

Hamilton, Bermuda, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs...

1 year ago - GlobeNewsWire

Hamilton, Bermuda, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical need...

1 year ago - GlobeNewsWire

Hamilton, Bermuda, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical need...

1 year ago - GlobeNewsWire

Auris Medical Holding Ltd. (EARS) CEO Thomas Meyer on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Auris Medical Holding AG (EARS) CEO Thomas Meyer on Q4 2018 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

About EARS

Auris Medical Holding Ltd., a clinical-stage biopharmaceutical company, developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy, and CNS disorders. The company's Phase 3 programs under the development include Keyzilen (AM-101) for the treatment of acute inner ear tinnitus; and Sonsuvi (AM-111) for the treatment of acute inner ear hearing loss. It is also developing AM-125 that is in Phase 2 clinical trial for the intranasal treatment of acute peripheral vertigo; AM-201, which has completed Phase ... [Read more...]

Industry
Biotechnology
IPO Date
Aug 6, 2014
CEO
Thomas Meyer
Employees
8
Stock Exchange
NASDAQ
Ticker Symbol
EARS
Full Company Profile

Financial Performance

Financial Statements